Mutual of America Capital Management LLC Sells 5,174 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mutual of America Capital Management LLC decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 167,103 shares of the biopharmaceutical company's stock after selling 5,174 shares during the period. Mutual of America Capital Management LLC's holdings in Gilead Sciences were worth $18,724,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of GILD. FMR LLC lifted its position in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the period. Wellington Management Group LLP lifted its position in Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after purchasing an additional 1,058,331 shares during the period. Geode Capital Management LLC lifted its position in Gilead Sciences by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after purchasing an additional 749,047 shares during the period. Norges Bank bought a new position in Gilead Sciences in the fourth quarter worth $1,789,254,000. Finally, Northern Trust Corp lifted its position in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the transaction, the chief financial officer directly owned 165,110 shares in the company, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the transaction, the insider owned 120,168 shares of the company's stock, valued at $13,238,908.56. This represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock valued at $6,340,745 in the last ninety days. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Down 4.3%

NASDAQ:GILD traded down $4.90 on Friday, hitting $109.64. 6,115,020 shares of the stock were exchanged, compared to its average volume of 7,702,954. The stock has a market capitalization of $136.38 billion, a price-to-earnings ratio of 23.08, a P/E/G ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 52 week low of $70.21 and a 52 week high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The company's 50-day moving average price is $107.74 and its 200 day moving average price is $104.68.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.32) EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were paid a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.88%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Analyst Ratings Changes

Several research analysts recently commented on GILD shares. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Oppenheimer cut their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Morgan Stanley lifted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Finally, JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average price target of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.